Alphabet Replaces Verizon in Dow Jones Industrial Average 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
PETALUMA, Calif., Feb. 05, 2016 -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (tradable warrants OCLSW) today announced that Jim Schutz, chief executive officer, and Bob Miller, chief financial officer, will present at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference to be held at the Convene Conference Center, 730 Third Avenue, New York City on Wednesday, February 10, 2016 at 9:30am ET. Management will also be meeting with investors throughout the day.
About Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company's products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.oculusis.com.
Media and Investor Contact: Oculus Innovative Sciences, Inc. Dan McFadden VP of Public and Investor Relations (425) 753-2105 [email protected]
